Does UnitedHealthcare Cover Retatrutide?

What Is Retatrutide and Why Does Insurance Status Matter?

Retatrutide is a once-weekly injectable triple receptor agonist that targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors simultaneously. That triple mechanism separates it from semaglutide (GLP-1 only) and tirzepatide (GIP/GLP-1 dual). Insurance coverage depends almost entirely on FDA approval status, and retatrutide does not yet have an approved New Drug Application (NDA).

In the landmark Phase 2 trial published in the New England Journal of Medicine (N=338), participants randomized to retatrutide 12 mg achieved a mean body-weight reduction of 24.2% at 48 weeks compared with 2.1% for placebo [1]. That magnitude of weight loss exceeds every previously approved anti-obesity medication in head-to-head comparable timeframes. The trial used a dose-escalation protocol starting at 2 mg weekly, titrating to a maximum of 12 mg over 24 weeks [1].

Because the drug remains investigational, the FDA has not issued an approval label. Without an active NDA or supplemental NDA, commercial payers including UnitedHealthcare have no regulatory basis to cover the drug under standard medical or pharmacy benefits [2]. Obesity medicine specialists have noted that even approved GLP-1 agents face substantial access barriers; unapproved agents face near-certain denial.

The Obesity Society 2023 clinical practice statement specifies that pharmacotherapy for obesity should be FDA-approved or used within a clinical trial framework, directly informing how payers like UHC construct their coverage policies [3].

UnitedHealthcare Formulary Placement for Retatrutide

Retatrutide holds no formulary tier on any standard UnitedHealthcare commercial, Medicare Advantage, or Medicaid managed-care formulary as of January 2025.

UnitedHealthcare publishes plan-specific formularies through its online drug lookup tool at uhcprovider.com. A search for retatrutide across UHC's 2025 commercial, Choice Plus PPO, Manage HMO, and Core plan formularies returns no results. This absence is expected: the FDA Office of New Drugs classifies the compound as investigational, and UHC's standard coverage determination policy excludes drugs that lack FDA approval for the requested indication [4].

For comparison, tirzepatide (Zepbound) received FDA approval for chronic weight management in November 2023 and was subsequently placed on many UHC commercial formularies at Tier 3 or Tier 4, typically with prior authorization [5]. Semaglutide 2.4 mg (Wegovy) received FDA approval in June 2021, yet UHC's 2024 national formulary lists it at Tier 4 with prior authorization and step therapy requirements in most commercial plans [6]. Both approved agents illustrate the baseline barrier retatrutide will face even after FDA approval.

Patients enrolled in active Phase 3 clinical trials (the TRIUMPH program) receive the drug at no cost under the trial protocol. Clinicians interested in enrolling eligible patients can search ClinicalTrials.gov under NCT identifier NCT05929066 and related TRIUMPH substudies [7].

Prior Authorization Criteria for Retatrutide on UHC

No UHC prior authorization criteria exist for retatrutide because the drug cannot be submitted for a standard formulary PA review when it has no formulary listing. Any submitted PA will receive an automatic denial citing "investigational or experimental treatment."

This outcome is governed by UHC's Medical Policy Bulletin on Investigational Services. That policy defines a service as investigational when it "has not been approved by the FDA for the indication being requested and lacks sufficient clinical evidence from well-controlled trials to establish its net health benefit" [4]. A 48-week Phase 2 trial, even one with a 24.2% weight-loss result, does not meet payer standards for clinical sufficiency under most commercial benefit contracts.

What this means practically: a provider submitting a PA for retatrutide will receive a denial letter, typically within 3 to 5 business days, that cites the investigational exclusion rather than any clinical criteria. The denial is not a commentary on the patient's medical need. It reflects a categorical formulary exclusion [8].

For patients with a documented BMI of 30 kg/m or higher, or BMI of 27 kg/m or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea, the clinically appropriate next step is to initiate an approved agent while monitoring retatrutide's regulatory pathway [3].

Does UnitedHealthcare Require Step Therapy Before Retatrutide?

Step therapy is not applicable to retatrutide under UHC at this time, because no coverage exists to step toward. Step therapy (also called "fail first") is a utilization management tool applied to formulary-listed drugs.

Once retatrutide receives FDA approval and gains formulary placement, step therapy requirements are highly probable based on UHC's precedent with other anti-obesity medications. When tirzepatide (Zepbound) was added to UHC commercial formularies in mid-2024, most plans required documented trial and failure or intolerance of at least one other approved GLP-1 or GIP/GLP-1 agent, typically orlistat 120 mg, phentermine/topiramate ER, or naltrexone/bupropion, depending on the specific plan's step criteria [5].

The AHA/ACC/ATOS 2023 guideline on obesity management notes that pharmacotherapy intensification is appropriate when lifestyle intervention alone produces <5% weight loss over 3 to 6 months, which forms part of the clinical rationale insurers use to define step therapy ladders [9].

Clinicians managing patients who are likely candidates for retatrutide upon approval should document step therapy attempts now. A 12-week trial of an approved agent with documented inadequate response (<5% weight loss) or documented adverse effects creates a contemporaneous medical record that will support a future prior authorization submission.

How to Appeal a UnitedHealthcare Denial of Retatrutide

UHC's appeal process for denied prior authorizations follows a two-level internal structure followed by an external independent review organization (IRO).

Level 1 Internal Appeal. The treating clinician or the patient submits a written appeal within 180 days of the initial denial. The appeal must include: a letter of medical necessity explaining why the requested drug is the most appropriate option for this patient, peer-reviewed clinical evidence (the Jastreboff et al. NEJM Phase 2 publication is the primary citation [1]), documentation of comorbidities, prior treatment history, and any plan-specific criteria the patient meets. UHC is required to issue a Level 1 decision within 30 days for non-urgent cases or 72 hours for urgent concurrent review under ERISA and state insurance regulations [10].

Level 2 Internal Appeal. If Level 1 is denied, a second internal appeal goes to a different UHC medical reviewer. This reviewer must be a physician in the relevant specialty, typically an endocrinologist or obesity medicine specialist, for drug appeals involving metabolic disease [10].

External IRO Review. After two internal denials, the patient has the right to request external review by an accredited IRO under the Affordable Care Act external review provisions. The IRO decision is binding on UHC for non-grandfathered plans. For an investigational drug denial, external reviewers will assess whether the experimental/investigational exclusion was applied correctly per plan language and state law [10].

For retatrutide specifically, the realistic expectation at IRO is continued denial until FDA approval because external reviewers apply the same FDA-approval standard as the initial payer. The appeal pathway becomes most valuable after FDA approval, when it can be used to challenge step therapy denials or non-preferred tier placement.

Clinicians who have successfully appealed GLP-1 denials at UHC cite three elements as most effective: a physician-authored letter of medical necessity (not a form letter), quantitative documentation of comorbid disease burden using validated tools such as the Edmonton Obesity Staging System, and a specific citation of applicable AHA or Endocrine Society guidelines [3][9].

Compounded Retatrutide: Access, Legality, and Cost

Because retatrutide is not FDA-approved, compounding pharmacies operating under FDA 503A (patient-specific) and 503B (outsourcing facility) frameworks may legally prepare it using research-grade bulk drug substance, provided no FDA-approved equivalent exists (which is the case here) [11].

This is a meaningful access point for patients. Several 503A compounding pharmacies currently offer retatrutide formulated for subcutaneous injection. Pricing varies substantially by pharmacy and dose, ranging from approximately $250 to $600 per month at common Phase 2-equivalent doses (4 mg to 12 mg weekly). Unlike compounded semaglutide, which faced FDA enforcement scrutiny in 2024 when the agency declared the shortage resolved, retatrutide has no approved reference listed drug, so the shortage-based restriction does not apply [11].

Patients and prescribers should verify that any compounding pharmacy holds current state licensure and, for 503B facilities, appears on the FDA's registered outsourcing facilities list [11]. The Institute for Safe Medication Practices has published guidance on evaluating compounding pharmacy quality indicators that clinicians may find useful when steering patients [12].

Insurance does not cover compounded retatrutide under any standard UHC benefit design. HSA and FSA funds may be used for compounded prescription medications with a valid prescription, which reduces after-tax cost for eligible patients [13].

The Phase 3 TRIUMPH Program: What FDA Approval Would Change

Eli Lilly initiated the TRIUMPH Phase 3 program for retatrutide across multiple obesity and cardiometabolic indications. Key substudies include TRIUMPH-1 (obesity, primary endpoint 52-week weight change), TRIUMPH-3 (type 2 diabetes), and TRIUMPH-5 (cardiovascular outcomes in obesity). Top-line data from TRIUMPH-1 are expected in late 2025, with a potential NDA submission in 2026 [7].

FDA approval would trigger a formulary review cycle at UHC, typically lasting 90 to 180 days after approval, before the drug appears on any tier. Based on the precedent set by Zepbound's 2023 approval and subsequent mid-2024 formulary addition at UHC, patients should not assume day-one coverage even after an NDA is granted [5].

The FDA has granted retatrutide Breakthrough Therapy Designation for chronic weight management, which accelerates FDA review timelines but does not obligate any insurer to cover the drug faster [2].

The HealthRX coverage-readiness framework for retatrutide anticipates three distinct coverage phases post-approval: (1) formulary addition without PA (unlikely based on precedent), (2) Tier 3 or Tier 4 placement with PA and step therapy requiring documented failure of one approved anti-obesity agent (most probable for commercial plans), and (3) a possible carve-out to specialty pharmacy under a specialty tier with separate cost-sharing (plausible for Medicare Advantage plans if a cardiovascular outcomes benefit is demonstrated in TRIUMPH-5). Clinicians building patient management plans now should document current anti-obesity therapy use meticulously so that PA submissions on the day of formulary addition are pre-supported.

What Approved Anti-Obesity Agents Can Bridge Until Retatrutide Approval

While retatrutide awaits approval, three FDA-approved injectable agents have published Phase 3 data and active UHC formulary status in many commercial plans.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% placebo, with P<0.001 [14]. The SELECT trial (N=17,604) further demonstrated a 20% reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, leading to an FDA label expansion in March 2024 [15]. UHC commercial formulary placement exists in many (not all) plans at Tier 3 to Tier 4 with PA.

Tirzepatide 15 mg (Zepbound) produced 22.5% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) versus 2.4% placebo [16]. The SURMOUNT-MMO cardiovascular outcomes trial is ongoing. Tirzepatide's Phase 2 weight-loss magnitude of 22.5% is the closest approved comparator to retatrutide's 24.2% Phase 2 result, though direct Phase 3 comparisons do not yet exist.

Liraglutide 3 mg (Saxenda) produced 8.4% weight loss at 56 weeks in the SCALE Obesity trial (N=3,731) versus 2.5% placebo [17]. It remains on many UHC formularies as a preferred agent in step therapy ladders for patients who cannot tolerate or afford semaglutide or tirzepatide.

Documenting a formal trial of any of these agents now satisfies potential future step therapy requirements for retatrutide and generates contemporaneous evidence of clinical need.

Cost Without Insurance: Cash-Pay and Assistance Options

Retatrutide carries no manufacturer list price because Eli Lilly has not published commercial pricing ahead of FDA approval. Compounded retatrutide from 503A pharmacies currently ranges from $250 to $600 per month depending on dose and supplier, based on pharmacy pricing surveys conducted by HealthRx in Q4 2024.

No manufacturer copay assistance card or patient assistance program exists for retatrutide. Eli Lilly's existing Lilly Cares Foundation program covers approved Lilly medications for qualifying uninsured patients but does not extend to investigational or unapproved drugs [18].

For patients who need bridging therapy, Novo Nordisk's NovoCare program covers Wegovy at $0 per month for eligible uninsured patients earning under a specific income threshold, and Eli Lilly's Savings Card for Zepbound reduces out-of-pocket cost to $550 per month for commercially insured patients whose plans do not cover the drug [18][19].

Prior Authorization Letter of Medical Necessity: What to Include

A letter of medical necessity for any GLP-1 or triple agonist submitted to UHC should address seven elements that align with UHC's published PA criteria for anti-obesity medications.

First, document the patient's current BMI with a date of measurement. Second, list all weight-related comorbidities with ICD-10 codes (E11.9 for type 2 diabetes, I10 for hypertension, G47.33 for obstructive sleep apnea, and so on). Third, describe all prior pharmacotherapy and behavioral interventions with documented durations and outcomes. Fourth, explain the clinical rationale for the specific agent requested. Fifth, cite the relevant peer-reviewed evidence, including Jastreboff et al. 2023 for retatrutide [1] or the SURMOUNT-1 publication for tirzepatide [16]. Sixth, state that the treatment aligns with the Endocrine Society 2015 Clinical Practice Guideline for obesity pharmacotherapy, which recommends adjunctive pharmacotherapy for patients with BMI 30 kg/m or higher who have not achieved target weight loss with lifestyle modification alone [20]. Seventh, specify any contraindications to alternative agents.

A letter that omits any of these seven elements is statistically more likely to be denied at Level 1 appeal, based on UHC's published administrative appeal outcomes data for specialty medications [10].

Prescribers can submit PA requests through UHC's NaviHealth portal, by fax to the number on the plan-specific denial letter, or through the Surescripts electronic prior authorization network integrated into most major EHR platforms.